CIT,
a European non-clinical CRO, announced the opening of its new U.S. subsidiary, CITox, Inc. The new company is based in Boston, Massachusetts, and will spearhead CIT’s planned expansion of its U.S. activities.
CIT simultaneously announced the appointment of Bernard Galat, 55, as Vice-President Business Development, North America. Galat is a U.S. citizen and will be based in the Boston office.
The U.S. represents 15 per cent of CIT’s current sales today, and the company aims to increase this to 30 per cent in three to five years.
“CIT is also pleased to introduce Bernard Galat and announce this key appointment as a further indication of our continued customer centric growth,” said Baratte.
Prior to joining CIT, Galat held senior sales and marketing positions with Xceleron Inc., Parexel International and Carestat, Inc. Formerly, he served as Vice President of Sales, Marketing and Clinical Applications for Ultracision, Inc. There, he recruited, trained and managed a global sales force and led cross-functional teams to establish priorities for new product development. Johnson & Johnson acquired Ultracision for a multiple equal to ten times sales.
Galat received a BS magna cum laude from Northeastern University in Biology and Communications and earned an MBA with honors from Northeastern’s Graduate School of Business.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.